Cantor Fitzgerald Predicts XFOR FY2025 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of X4 Pharmaceuticals in a research note issued to investors on Tuesday, April 1st. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings of ($0.35) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $3.00 price objective on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its earnings results on Tuesday, March 25th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $1.43 million during the quarter, compared to analysts’ expectations of $1.07 million.

Separately, HC Wainwright reiterated a “buy” rating and set a $1.50 target price on shares of X4 Pharmaceuticals in a research note on Thursday, March 27th.

X4 Pharmaceuticals Stock Up 2.2 %

XFOR opened at $0.21 on Thursday. The business has a 50 day moving average of $0.41 and a 200-day moving average of $0.50. The stock has a market capitalization of $37.27 million, a price-to-earnings ratio of -2.38 and a beta of 0.58. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals has a 1-year low of $0.19 and a 1-year high of $1.45.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Acorn Capital Advisors LLC bought a new stake in shares of X4 Pharmaceuticals in the 4th quarter worth about $5,363,000. Geode Capital Management LLC increased its holdings in shares of X4 Pharmaceuticals by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 3,497,212 shares of the company’s stock worth $2,566,000 after buying an additional 49,700 shares in the last quarter. State Street Corp raised its stake in shares of X4 Pharmaceuticals by 6.8% in the third quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after acquiring an additional 189,105 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of X4 Pharmaceuticals by 2.9% in the 4th quarter. Northern Trust Corp now owns 1,357,539 shares of the company’s stock worth $996,000 after acquiring an additional 37,940 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its position in X4 Pharmaceuticals by 4.0% during the 4th quarter. Point72 Asset Management L.P. now owns 650,000 shares of the company’s stock worth $477,000 after acquiring an additional 24,948 shares during the last quarter. 72.03% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Paula Ragan sold 76,473 shares of the stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $34,412.85. Following the completion of the transaction, the chief executive officer now directly owns 1,087,386 shares of the company’s stock, valued at approximately $489,323.70. This represents a 6.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Adam S. Mostafa sold 74,773 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $33,647.85. The disclosure for this sale can be found here. In the last quarter, insiders sold 202,663 shares of company stock worth $91,198. 1.62% of the stock is currently owned by company insiders.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.